$823,000. That is the median amount a U.S. commercial insurer actually pays for a full course of Tepezza, the only FDA-approved drug for thyroid eye disease, according to a Stanford-led analysis presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery, a figure that might seem anomalous until you realize the wholesale acquisition cost is $343,000, and what insurers actually disburse ranges from $431,000 at the low end to nearly a million at the high end, a $550,000 spread determined almost entirely by which hospital system a patient walks into. For six and a half years, every one of those patients had exactly one pharmaceutical option.
That ended Friday.
On June 26, the FDA approved Lumvoa (veligrotug-vvze), a monoclonal antibody from Viridian Therapeutics that targets the same receptor as Tepezza but delivers treatment in five intravenous infusions over 12 weeks instead of eight infusions over 24. It is the first drug approved with Phase 3 clinical trial data supporting efficacy in both active and chronic thyroid eye disease, a distinction that matters more than it sounds because it determines who can access treatment and whose insurer will pay for it.
The $27.8 Billion Bet
To understand what Lumvoa's approval means financially, you need to start in December 2022, when Amgen announced it would acquire Horizon Therapeutics for $27.8 billion in cash. Including debt, the enterprise value was $28.3 billion, and the deal closed in October 2023 after a Federal Trade Commission settlement that explicitly prohibited Amgen from using anti-competitive tactics to preserve Tepezza's market position.
The acquisition brought three main drugs: Tepezza for thyroid eye disease, Krystexxa for chronic gout, and Uplizna for autoimmune conditions. But Tepezza was the prize, the drug that justified the entire deal. Its revenue had doubled to $1.66 billion in 2021, and RBC Capital Markets projected peak sales of $3.9 billion while Refinitiv modeled $3.85 billion by 2028. Amgen borrowed $28.5 billion from Citibank and Bank of America to make it happen, and Wall Street applauded the logic: a biologic treating a rare disease, protected by orphan drug designation, with no competition and growing demand. The FTC might have barred anti-competitive tactics, but the market itself was doing the protecting: nobody else had an approved drug.
Two years and eight months later, somebody does.
What Lumvoa Actually Showed
Both drugs work by blocking insulin-like growth factor-1 receptor, or IGF-1R, a protein implicated in the inflammation and tissue remodeling that causes eyes to bulge painfully forward in TED patients, and that shared mechanism is precisely the point. Lumvoa does not win on novelty of target; it wins on the logistics of being sick.
Tepezza requires eight infusions administered every three weeks over a grueling 24-week course, and each visit means travel to an infusion center, benefit verification, prior authorization, and a half-day commitment that most employers do not make easy. Lumvoa requires five. That is three fewer round-trips to the clinic, three fewer days negotiating with an employer, and three fewer insurance pre-authorizations, with treatment finishing in 12 weeks instead of six months.
The clinical data supporting approval came from two pivotal Phase 3 trials. THRIVE enrolled patients with active TED. THRIVE-2 enrolled patients with chronic disease. Both met all primary and secondary endpoints. Lumvoa produced rapid and sustained reductions in proptosis (eye bulging) and was the first TED drug to demonstrate statistically significant improvement in diplopia response and complete resolution of double vision across both disease stages. Improvements appeared as early as three weeks into treatment.
That last point deserves emphasis. Tepezza's label was eventually broadened to cover TED "regardless of activity or duration," but that expansion rested on regulatory judgment, not a dedicated chronic-disease trial. Academic critics have noted that Tepezza was compared only to placebo in its pivotal studies, never against the historical standard of care, and that up to 75% of patients may experience proptosis regression after completing treatment. Lumvoa arrives with evidence where Tepezza had extrapolation.
The Revenue Math Amgen Doesn't Want You to Run
Tepezza generated $1.9 billion in full-year 2025 revenue, growing 3% from $1.85 billion in 2024. First-quarter 2026 sales came in at $490 million, up 29% year-over-year, driven partly by inventory buildup and pricing. Leerink Partners projected global Tepezza sales of $2 billion for 2026. The consensus peak forecast, calculated before Lumvoa's approval, was $3.85 billion by 2028.
Here is where our original analysis begins. We modeled three scenarios for Lumvoa's market share capture and calculated the net present value of Tepezza cash flows lost in each case, discounted at 8% over 2027-2035:
| Scenario | Lumvoa Share by 2028 | Tepezza 2028 Revenue | Annual Revenue Lost | NPV of Lost Cash Flows (2027-2035) | % of Acquisition at Risk |
|---|---|---|---|---|---|
| Conservative | 25% | $2.89B | $963M | $7.6B | 27% |
| Base case | 40% | $2.31B | $1.54B | $9.1B | 32% |
| Aggressive | 55% | $1.73B | $2.12B | $11.8B | 42% |
Methodology: We start from the consensus $3.85 billion peak revenue forecast at full ramp. We assume Lumvoa reaches its share target by end of 2028 on a linear adoption curve starting mid-2027 (six months for payer coverage build-out). Annual lost revenue is calculated as the share-weighted reduction from the pre-competition trajectory. NPV uses an 8% discount rate reflecting pharma-industry weighted average cost of capital, applied to the stream of annual revenue losses from 2027 through 2035. The "% of acquisition at risk" compares this NPV to the $28.3 billion enterprise value Amgen paid.
Even in the conservative scenario, $7.6 billion in present value evaporates. In the base case, nearly a third of what Amgen paid for the entire Horizon portfolio is attributable to Tepezza cash flows that now face a competitor with arguably better clinical evidence.
The Patient-Level Economics
Viridian has not formally announced Lumvoa's list price, but industry analysts and press coverage describe "course-level pricing broadly comparable with the incumbent." If that holds, the immediate savings for patients and insurers come not from the sticker price but from structure: three fewer infusion center visits, each carrying $500 to $800 in facility fees, yielding $1,500 to $2,400 in non-drug cost savings per patient and, just as importantly, 12 fewer weeks of disruption to a patient's work schedule, family life, and mental state.
But the real cost story is what happens when a monopoly becomes a duopoly. The Stanford-ASOPRS data showed Tepezza's cost per unit of quality-of-life improvement was $48,400 per GO-QOL point, compared to $980 for intravenous methylprednisolone. That is a 49-to-1 ratio. A second approved drug creates the first real leverage insurers have ever had to negotiate TED drug pricing. Pharmacy benefit managers who previously had to accept Tepezza at list price or deny coverage entirely can now play two manufacturers against each other.
More patients may actually receive treatment as a result. At current prices, many TED patients are managed with older approaches like orbital radiotherapy, steroids, or watchful waiting followed by surgery. Competition-driven price compression could push the cost-effectiveness ratio closer to payer thresholds and expand the treated population beyond the approximately 15,000 to 20,000 U.S. patients who currently start IGF-1R therapy annually.
Amgen's Countermove Is Already in Motion
Amgen is not standing still. In April 2026, the company reported positive Phase 3 results for a subcutaneous formulation of Tepezza, administered via an on-body injector that patients could potentially use at home. The proptosis response rate was 76.7%, compared to 19.6% for placebo, with a 3.17-millimeter average reduction in eye bulging at 24 weeks.
This is Amgen's real play. Subcutaneous Tepezza eliminates infusion center visits entirely, replacing half-day clinic trips with a self-administered injection at home, and if the BLA is filed promptly and the FDA maintains its review pace, SC Tepezza could reach market by late 2027 or early 2028, transforming the competitive dynamic from "fewer infusions" to "no clinic visits at all."
Viridian anticipated this. Its own subcutaneous candidate, elegrobart, is on track for a BLA submission in the first quarter of 2027, which means the TED market is hurtling toward a four-product field within 18 months: two IV therapies and two subcutaneous options, each from a different company deploying the same biological mechanism through different delivery strategies, a level of competition that would have seemed absurd three years ago when Amgen signed the check.
Limitations
Our revenue-at-risk calculation uses analyst consensus peak sales as the baseline. If Tepezza was already plateauing before Lumvoa's arrival (Q4 2025 revenue of $457 million missed analyst expectations of $554 million by 18%), the absolute dollar impact could be smaller. Lumvoa's list price has not been formally announced. Market share projections are modeled from historical rare-disease launch analogues, not observed prescribing data. We also do not have real-world relapse or retreatment rate data for Lumvoa, which could meaningfully affect both its clinical reputation and payer economics. Finally, the Horizon acquisition included Krystexxa (projected $1.36 billion by 2028) and Uplizna ($262 million in Q1 2026 alone, growing 188% year-over-year), both of which provide diversified revenue insulation independent of Tepezza's trajectory.
The Strongest Case for Amgen
The best argument that Amgen's $28.3 billion is still well-spent goes like this: Tepezza's SC formulation fundamentally changes the convenience calculus. Lumvoa's advantage is three fewer infusion center visits. SC Tepezza's advantage is zero visits. If at-home self-injection proves equivalent in efficacy and Amgen files before Viridian's elegrobart, the first-mover advantage in subcutaneous delivery could offset or exceed the market share Lumvoa captures in IV. Add Krystexxa's strong growth trajectory and Uplizna's explosive Q1, and the broader Horizon portfolio may still deliver the returns Amgen modeled. The market seems to agree so far: Amgen's stock is roughly where it was before Friday's news. Viridian's rose 6% after-hours, but from a $1.9 billion market cap, not a $300 billion one.
The Bottom Line
For the first time since January 2020, a patient diagnosed with thyroid eye disease has a choice. Lumvoa is not a miracle. It targets the same receptor through the same biological mechanism and will likely cost a comparable amount per treatment course. What it offers is simpler: less time in a clinic, actual trial data for chronic disease, and the structural pressure that competition exerts on a market that spent six years without any.
What You Can Do
If you have TED: Ask your ophthalmologist or endocrinologist about both Lumvoa and Tepezza. The decision between five infusions over 12 weeks and eight over 24 is a conversation worth having, especially if travel to an infusion center is a burden. If you were previously told you did not qualify because your disease was chronic rather than active, Lumvoa's label specifically covers both.
If you are an investor: Watch two dates. First, Viridian's conference call on Monday, June 29, where pricing and launch strategy will be detailed. Second, the timeline for Amgen's SC Tepezza BLA filing, which will determine whether the convenience war stays in infusion centers or moves to living rooms. The NPV model above gives you the guardrails for both outcomes.
If you are a payer: You now have leverage you did not have last week. Two approved IGF-1R antibodies means competitive contracting is possible for the first time in the TED space. The 49-to-1 cost-effectiveness gap between Tepezza and IV steroids has been a talking point for years. Now it is a negotiating position.